NCT05159908 - A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions

Focal Onset SeizureFocal Onset Epilepsy

Interventions

DRUG

NBI-921352

Tablets for oral administration

DRUG

Placebo

Matching placebo tablets for oral administration

Trial Locations (28)

1070

Neurocrine Clinical Site, Brussels

1145

Neurocrine Clinical Site, Budapest

2031

Neurocrine Clinical Site, Randwick

3000

Neurocrine Clinical Site, Leuven

3050

Neurocrine Clinical Site, Parkville

3065

Neurocrine Clinical Site, Melbourne

3079

Neurocrine Clinical Site, Ivanhoe

3181

Neurocrine Clinical Site, Prahran

4032

Neurocrine Clinical Site, Debrecen

7623

Neurocrine Clinical Site, Pécs

9000

Neurocrine Clinical Site, Ghent

20133

Neurocrine Clinical Site, Milan

27100

Neurocrine Clinical Site, Pavia

28034

Neurocrine Clinical Site, Madrid

28040

Neurocrine Clinical Site, Madrid

31059

Neurocrine Clinical Site, Toulouse

35033

Neurocrine Clinical Site, Rennes

40139

Neurocrine Clinical Site, Bologna

46026

Neurocrine Clinical Site, Valencia

59037

Neurocrine Clinical Site, Lille

69677

Neurocrine Clinical Site, Bron

656 91

Neurocrine Clinical Site, Brno

708 52

Neurocrine Clinical Site, Ostrava

150 06

Neurocrine Clinical Site, Prague

160 00

Neurocrine Clinical Site, Prague

186 00

Neurocrine Clinical Site, Prague

516 01

Neurocrine Clinical Site, Rychnov nad Kněžnou

08035

Neurocrine Clinical Site, Barcelona